NASDAQ · Health care

Soligenix, Inc. (SNGX)

It posted a net loss of $10.2M. In fiscal 2025 capital spending exceeded operating cash flow by $10.3M. At June 30, 2026 it held $9.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 7, 2026.

Price

$0.38

-0.47% on the day · September 25, 2026

52-week range $0.28 to $1.97

Market cap

$8.4M

What Soligenix, Inc. does

Soligenix, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SNGX.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	n/a	-$11.8M	-$11.1M	-$2.14	-$10.3M
2024	$119.4K	-$9.4M	-$8.3M	-$4.98	n/a
2023	$839.4K	-$7.7M	-$6.1M	-$12.66	n/a
2022	$948.9K	-$14.2M	-$13.8M	-$77.08	n/a
2021	$824.3K	-$13.1M	-$12.6M	-$75.16	n/a
2020	$2.4M	-$18.6M	-$17.7M	-$155.17	n/a

Full financial statements: income, balance sheet and cash flow

Next report expected around November 6, 2026.

Estimated from its filing rhythm: about 91 days after its last report of August 7, 2026, its usual gap. Not a date the company has announced. See the report calendar

Latest SEC filings

What Soligenix, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 21, 2026
Bylaws or fiscal year changed 8-K
August 7, 2026
Securities offering prospectus 424B3
August 7, 2026
Securities offering prospectus 424B3
August 7, 2026
Securities offering prospectus 424B3
August 7, 2026
Securities offering prospectus 424B3
August 7, 2026
Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$0.12 versus -$0.82.
August 3, 2026
Annual report to shareholders ARS
August 3, 2026
Additional proxy material DEFA14A
August 3, 2026
Proxy statement DEF 14A
July 23, 2026
Form PRER14A filing PRER14A

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 18, 2026. Insider transactions on SEC

Insider trades

What the people running Soligenix, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

Bought (open market)

last 90 days

Sold

last 90 days

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns SNGX

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Holder	Of class	Shares	Filed
Michael Liu13G, passive with 2 related filers	5.7%	983,588	June 25, 2026

Latest filings below 5%: Armistice Capital, LLC 4.99% (February 17, 2026).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

We have not read this company's Form 4 filings yet.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about SNGX

What does Soligenix, Inc. do?

Soligenix, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SNGX.

Is Soligenix, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $10.2M.

When did Soligenix, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 7, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the bylaws or fiscal year changed from September 21, 2026.

Similar companies

Compare SNGX with

Compare SNGX with any company

Follow SNGX

Get an email when Soligenix, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow SNGX: get an email when it files

Where the numbers come from

Financial figures are the values Soligenix, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.